ANTICOAGULATION, BLEEDING, AND IMMUNOTHROMBOSIS IN CRITICALLY ILL PATIENTS WITH COVID-19

JUAN PAEZ VARGAS, Laura Prieto-Pérez(Hospital Universitario Fundación Jiménez Díaz), Denis Robaglia, Javier Flandes, Ánxela Vidal González, Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), José Fortes Alen(Hospital Universitario Fundación Jiménez Díaz), Pilar Llamas(Hospital Universitario Fundación Jiménez Díaz), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), César Calvo(Hospital Universitario Fundación Jiménez Díaz)
CHEST Journal
October 1, 2021
10.1016/j.chest.2021.07.926
Cited by 3

Related Papers

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247